Cenicriviroc

Cenicriviroc (CVC) is currently in clinical development for non-alcoholic steatohepatitis (NASH) in adults with liver fibrosis and primary sclerosing cholangitis (PSC).

Over 600 unique subjects have been exposed to CVC in completed studies, including 440 subjects participating in Phase 1 studies and 159 HIV infected subjects participating in Phase 2 studies. 

CVC is a dual inhibitor of the CCR2 and CCR5 pathways which play a key role in the cycle of inflammation and fibrosis. CVC has been shown in clinical trials to bind to both CCR2 and CCR5 targets.

Mechanism of Action

Immune and inflammatory response to liver cell damage is mediated through a well-described signaling network of liver and immune cells. An accumulation of fat in the liver causes injury, and Kupffer cells sense the tissue injury and are the first responders to liver cell damage. Activated Kupffer cells initiate an inflammatory response to the liver injury. Ultimately, Kupffer cells and other pro-inflammatory macrophages activate hepatic stellate cells that differentiate into cells responsible for liver fibrosis. The CCR2 and CCR5 signaling pathways play a central role throughout this process.

More information

Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design

CENTAUR, a Phase 2b Efficacy and Safety Study of Cenicriviroc in Adults with Non-alcoholic Steatohepatitis and Liver Fibrosis at Increased Risk of Progression to Cirrhosis

A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus

Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis

Clinical Trials

CENTAUR Phase 2b for nonalcoholic steatohepatitis (NASH) in adults with liver fibrosis

PERSEUS Phase 2a for primary sclerosing cholangitis

CVC for NASH

Stage

Phase 2b

Prevalence

3-5% of US population
2-4% worldwide

CVC for PSC

Stage

Phase 2a

Prevalence

44,000 US patients
Similar prevalence in Europe